<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964636</url>
  </required_header>
  <id_info>
    <org_study_id>VVR_2019_6</org_study_id>
    <nct_id>NCT03964636</nct_id>
  </id_info>
  <brief_title>Contraceptive Pills and Retinal Vascularization</brief_title>
  <acronym>PILURET</acronym>
  <official_title>Contraceptive Pills and Retinal Vascularization (Piluret)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main hypothesis is the taking of combined 1st and 2nd generation or 3rd and 4th
      generation oral contraceptives is associated with a change in retinal micro-vascularization
      compared to the absence of combined oral contraceptive intake.

      Women of childbearing age will be recruited during their ophthalmologic consultation at the
      Rothschild Foundation, an OCT-A will be realized and data relating to their medical and
      ophthalmologic history and their oestro-progestative contraceptive intake will be collected.

      The objective is to find an association between retinal vascular density and combined oral
      contraceptives intake.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Density of retinal vascular Plexus (quantitative variable expressed as a percentage) using OCT-A.</measure>
    <time_frame>At the inclusion consultation</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Combined Oral Contraceptives Intake</condition>
  <arm_group>
    <arm_group_label>no contraceptive intake</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>combined 1st/2nd generation oral contraceptives intake</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>3rd/4th generation combined oral contraceptives intake</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OCT-A (optical coherence tomography)</intervention_name>
    <description>Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.</description>
    <arm_group_label>3rd/4th generation combined oral contraceptives intake</arm_group_label>
    <arm_group_label>combined 1st/2nd generation oral contraceptives intake</arm_group_label>
    <arm_group_label>no contraceptive intake</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women of chilbearing age presenting to an ophthalmologic consultation at the Foundation
        Rothschild will be included in one of the 3 groups: no contraceptive intake, combined
        1st/2nd generation oral contraceptives and 3rd/4th generation combined oral contraceptives,
        if they meet the inclusion and non-inclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  for the control group : No Estro-progestin contraceptive treatment (oral, transdermal)
             for at least 6 months

          -  for the cases under combined 1st and 2nd generation pills : Estro-progestin
             contraceptive treatment for at least 6 months

          -  for the cases under combined 3rd and 2th generation pills: Estro-progestin
             contraceptive treatment for at least 6 months

        Exclusion criteria:

          -  Menopausal woman

          -  Ametropia greater than + 3 hyperopia diopters or-3 myopia diopters

          -  Astigmatism greater than 2 dioptres

          -  Smoking patient (cigarette or e-cigarette)

          -  Caffeine intake within 2 hours prior to the OCT-A exam

          -  Any known retinal pathology

          -  Antecedent of deep vein thrombosis or deep arterial thrombosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Vivien Vasseur</last_name>
    <phone>+33148036440</phone>
    <email>vvasseur@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Am√©lie Yavchitz</last_name>
    <phone>+33148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivien VASSEUR</last_name>
      <phone>148036440</phone>
      <phone_ext>+33</phone_ext>
      <email>vvasseur@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCT-A</keyword>
  <keyword>combined oral contraceptives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

